 | ||
 | | |
 | ||
 | ||
 | | |
| | |
|
 |
|
|
||
 |
||
|
||
| Les informations publiées par la revue Prescrire
présentent un intérêt bien au delà des
limites de la francophonie. C’est pourquoi l’Association
Mieux Prescrire a décidé de publier régulièrement,
depuis 1992, des sélections de textes de la revue Prescrire
en anglais, langue la plus utilisée aujourd’hui par la
communauté médicale et pharmaceutique mondiale. Prescrire International regroupe, tous les deux mois, une sélection de textes de la revue Prescrire, minutieusement traduits en anglais par des professionnels anglophones, sous le contrôle de la Rédaction de la revue Prescrire. L’abonnement d’un an à Prescrire International comprend la livraison de 6 numéros de 40 pages et d’un index détaillé couvrant les 5 dernières années. Les abonnés à Prescrire International, répartis dans près de 70 pays, sont parfois des praticiens de terrain, mais le plus souvent des "personnes relais" (universitaires, responsables d’associations de formation, de centres de documentation, d’agences administratives ou d’évaluation du médicament, etc.). |
 |
|
|
||
|
||
| Prescrire International is the concise, English language version of la revue Prescrire. Prescrire International is a unique source of independent comparative information on drugs and other therapeutic interventions. The New Drugs section provides you with comparative assessments of new drugs and news indications. The Reviews section gives you assessments of therapeutic interventions as well as treatment guidelines that will help you to offer your patients effective care based on the best availabe evidence. The Adverse Effects section gives you a balanced view of the latest suspected or confirmed adverse drug reaction data collected from the many published and unpublished data sources all over the world. |  |
|
|
||
|
||
| Prescrire International n°94, April 2008 | ||
|
||
| Editorial Hypocrisy EU regulators put asthma patients at risk (p. 46) |
||
|
||
| New Products Aliskiren (arterial hypertension) No evidence of clinical efficacy (p. 47) |
||
|
||
| Carglumic acid (rare urea cycle disorder - a second
look) Confirmed progress (p. 50) |
||
|
||
| 0.4% glyceryl trinitrate ointment (chronic anal fissures) Not useful (p. 52) |
||
|
||
| Artemether + lumefantrine (uncomplicated malaria) An alternative to atovaquone + proguanil (p. 54) |
||
|
||
| Budesonide + formoterol (asthma attacks) A step backwards (p. 57) |
||
|
||
| 7-valent pneumococcal vaccine (otitis) No tangible efficacy (p. 58) |
||
|
||
| Common stems - INNs -tocin and -kiren (p. 58) |
||
|
||
| Levetiracetam (tonic-clonic seizures) Another second-line option (p. 59) |
||
|
||
| Celecoxib Still around, unfortunately (p. 59) |
||
|
||
| Shortcuts. Rotigotine (p. 60) | ||
|
||
| Adverse Effects Drug-induced interstitial pneumonia (p. 61) |
||
|
||
| Etonogestrel contraceptive implant: ulnar nerve damage (p. 63) | ||
|
||
| Rhabdomyolysis linked to Chinese red yeast rice (p. 64) | ||
|
||
| Misoprostol and pregnancy: risk of malformations (p. 65) | ||
|
||
| Telithromycin: visual disorders, myasthenia (p. 66) | ||
|
||
| Adverse drug effects: in children too (p. 66) | ||
|
||
| Mesotherapy: mycobacteriosis (p. 67) | ||
|
||
| Codeine: death of a breastfed newborn (p. 67) | ||
|
||
| Domperidone and sudden death (p. 67) | ||
|
||
| Etonogestrel implants: drug interactions and unintended pregnancies (p. 67) | ||
|
||
| Reviews Osteodensitometry in healthy postmenopausal women Useful for avoiding unecessary treatment (p. 68) Prescrire's advice: Bone mineral density measurement and fracture prevention after the menopause (p. 72) |
||
|
||
|
Minireviews |
||
|
||
| Outlook 2007 Prescrire Awards (p. 74) |
||
|
||
| New medicines in 2007: regulatory agencies and policy makers leave public health in the hands of the pharmaceutical industry (p. 78) | ||
|
||
| Drug packaging in 2007: some improvements, still many
risks (p. 82) Prescrire's advice: Drug packaging: preventing bedside confusion (p. 82) |
||
|
||
| Medication errors Drug regulatory agencies maintain confusion between brand names (p. 83) |
||
|
||
|
||
|
|
|
